Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry

International Journal of Rheumatic Diseases

Volumn 21, Issue 1, 2018, Pages 170-178

  Narongroeknawin, Pongthorn ^a   Chevaisrakul, Parawee ^b   Kasitanon, Nuntana ^c   Kitumnuaypong, Tasanee ^d   Mahakkanukrauh, Ajanee ^e   Siripaitoon, Boonjing ^f   Katchamart, Wanruchada ^g  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d RAJAVITHI HOSPITAL   (Thailand)

^e KHON KAEN UNIVERSITY   (Thailand)

^f PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

Author keywords

biological DMARDs; drug survival; reason for discontinuation; rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; RITUXIMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; ADVERSE OUTCOME; ARTICLE; ASPIRATION PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HEPATITIS B; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOBACTERIOSIS; PRIORITY JOURNAL; REMISSION; RETENTION TIME; RHEUMATOID ARTHRITIS; RISK FACTOR; SURVIVAL RATE; THAI (PEOPLE); TREATMENT OUTCOME; ADVERSE DRUG REACTION; AGED; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG RESISTANCE; DRUG SUBSTITUTION; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; THAILAND; TIME FACTOR;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REMISSION INDUCTION; RISK FACTORS; THAILAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 84996602311     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12937     Document Type: Article

References (37)

1. Mottonen T, Hannonen P, Leirisalo-Repo M et al. (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 353, 1568–73.
2. Grigor C, Capell H, Stirling A et al. (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 264, 263–9.
3. Bakker MF, Jacobs JWG, Verstappen SMM, Bijlsma JWJ (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66, iii56–60.
4. Verstappen SMM, Jacobs JWG, van der Veen MJ et al. (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66, 1443–9.
5. Singh JA, Furst DE, Bharat A et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64, 625–39.
6. Smolen JS, Landewe R, Breedveld FC et al. (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73, 492–509.
7. Gaujoux-Viala C, Gossec L, Cantagrel A et al. (2014) Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spine 81, 287–97.
8. Deighton C, Hyrich K, Ding T et al. (2010) BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology 49, 1197–9.
9. Albrecht K, Kruger K, Wollenhaupt J et al. (2014) German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 34, 1–9.
10. Nam JL, Ramiro S, Gaujoux-Viala C et al. (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73, 516–28.
11. Bergman GJD, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39, 425–41.
12. Kourbeti IS, Ziakas PD, Mylonakis E (2014) Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis 58, 1649–57.
13. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al. (2012) Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308, 898–908.
14. Mariette X, Matucci-Cerinic M, Pavelka K et al. (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70, 1895–904.
15. Food and Drug Administration Thailand. Hello@FDA.Single.Window 2015 [19 July 2015]. Available from: http://fdaolap.fda.moph.go.th/logistics/drgdrug/DSerch.asp.
16. Thai Rheumatism Association. Guideline for Biologic Therapy in Rheumatic Diseases 2006 [12 June 2015]. Available from: http://www.thairheumatology.org/download/guideline_biolo_gic_therapy.pdf.
17. Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315–24.
18. Aletaha D, Neogi T, Silman AJ et al. (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62, 2569–81.
19. Richter A, Strangfeld A, Herzer P et al. (2014) Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register. Arthritis Care Res (Hoboken) 66, 1627–33.
20. McGonagle D, Tan AL, Madden J, Taylor L, Emery P (2008) Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) 47, 865–7.
21. Hetland ML, Christensen IJ, Tarp U et al. (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62, 22–32.
22. Listing J, Strangfeld A, Rau R et al. (2006) Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low–results from RABBIT, the German biologics register. Arthritis Res Ther 8, R66.
23. Iannone F, Gremese E, Gallo G et al. (2014) High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register. Clin Rheumatol 33, 31–7.
24. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47, 495–9.
25. Askling J, Fored CM, Geborek P et al. (2006) Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 65, 707–12.
26. Greenberg JD, Reed G, Decktor D et al. (2012) A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71, 1134–42.
27. Dixon WG, Watson K, Lunt M et al. (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54, 2368–76.
28. Atzeni F, Sarzi-Puttini P, Botsios C et al. (2012) Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12, 225–9.
29. Favalli EG, Desiati F, Atzeni F et al. (2009) Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 8, 266–73.
30. Komano Y, Tanaka M, Nanki T et al. (2011) Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38, 1258–64.
31. Sakai R, Cho SK, Nanki T et al. (2015) Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther 17, 74.
32. World Bank Group. Incidence of tuberculosis (per 100,000 people) 2015 [19 July 2015]. Available from: http://data.worldbank.org/indicator/SH.TBS.INCD.
33. Navarra SV, Tang B, Lu L et al. (2014) Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis 17, 291–8.
34. CancerIndex. Thailand: cancer statistics from IARC GlobalCan 2012 [19 July 2015]. Available from: http://www.cancerindex.org/Thailand.
35. Aaltonen KJ, Joensuu JT, Virkki L et al. (2015) Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 42, 372–8.
36. Slimani S, Lukas C, Combe B, Morel J (2011) Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 78, 484–7.
37. Hainsworth JD (2003) Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther 5 (Suppl. 4), S12–6.